compliance

News
Samsung Bioepis' Remicade rival approved in EU

Samsung Bioepis' Remicade rival approved in EU

Merck, Sharp and Dohme's (MSD) inflammatory diseases blockbuster Remicade (infliximab) faces further biosimilar competition after Samsung Bioepis' rival, Flixabi, was approved in Europe.